Medicina: Artículos: Medicina : [47]  Estadísticas

Buscar por 
Suscribirse para recibir un email cada vez que se introduzca un ítem en esta colección. RSS Feed RSS Feed RSS Feed
Ítems de la colección (ordenados por Fecha Publicación en orden Descendente): 1 a 20 de 47
Vista previaFecha de publicaciónFecha de CreaciónTítulo
Circulating ST2, from biomarker to pathogenic mediator.pdf.jpgsep-2023-Circulating ST2, from biomarker to pathogenic mediator
Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55aYY1sST2 signaling axis.pdf.jpgmay-2023-Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis
1-s2.0-S0753332222014536-main.pdf.jpg2023-Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?
s11606-022-07567-5.pdf.jpg2023-The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
Myocardial Remodeling Mechanisms and Translational Implications.pdf.jpgmay-2022-Myocardial Remoding: Mechanisms and Translational Implications
AJT-22-1321.pdf.jpgmay-2022-Critical warm ischemia time point for cardiac donation after circulatory death
feb-2021-The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI
TH founder_2021s-0040-1716531.pdf.jpg2021-Antithrombin p.Thr147Ala: The First Founder Mutation in People of African Origin Responsible for Inherited Antithrombin Deficiency
41598_2020_Article_70454.pdf.jpgago-2020-Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
TH 2020.pdf.jpg2020-Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project.
Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabete.pdf.jpgoct-2019-Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
Reply_Interleukin-1β and sST2.pdf.jpgjul-2019-Reply: Interleukin-1β and sST2
Temporal characterization of cardiac expression.pdf.jpgabr-2019-Temporal characterization of cardiac expression of glucose transporters SGLT and GLUT in an experimental model of myocardial infarction
The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure.pdf.jpgmar-2019-The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure
MPI 2019.pdf.jpg2019-MPI-CDG with transient hypoglycosylation and antithrombin deficiency
delamorena-barrio2020_Blood.pdf.jpg2019-Archeogenetics of F11 p.Cys38Arg: a 5400-year-old mutation identified in different southwestern European countries
Herwald_Article_PDF_1574947964_1.pdf.jpg2019-A human antithrombin isoform dampens inflammatory responses and protects from organ damage during bacterial infection
Noncardiac Production of Soluble ST2 in ST-Segment Elevation Myocardial Infarction.pdf.jpgsep-2018-Noncardiac Production of Soluble ST2 in ST-Segment Elevation Myocardial Infarction
Enhancing the  real world  prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers.pdf.jpg2018-Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers.
Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model.pdf.jpgdic-2017-Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model of Acute Myocardial Infarction
Ítems de la colección (ordenados por Fecha Publicación en orden Descendente): 1 a 20 de 47